Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors

    Basic Details
    Date
    Tuesday, January 24, 2023
    Type
    Publication
    Description

    Data on angioedema risk among sacubitril-valsartan (SV) users in real-world settings are limited. We sought to evaluate the risk of angioedema among SV new users compared with angiotensin-converting enzyme (ACE) inhibitor and angiotensin-receptor-blocker (ARB) new users separately.

    We conducted a propensity score–matched cohort study, comparing SV new users (no use of SV, ACE inhibitor, ARB 6 months before) and SV new users with prior use (within 183 or 14 days) of ACE inhibitor or ARB (ACE inhibitor–SV and ARB-SV users; recent ACE inhibitor–SV and recent ARB-SV users, respectively) vs ACE inhibitor and ARB new users separately.

    Author(s)

    Efe Eworuke, Emily C Welch, Nicole Haug, Casie Horgan, Hye Seung Lee, Yueqin Zhao, Ting-Ying Huang

    Corresponding Author

    Efe Eworuke; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

    Email: efe.eworuke@fda.hhs.gov